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HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
FbsA, a fibrinogen-binding protein from Streptococcus agalactiae,
mediates platelet aggregation
Giampiero Pietrocola, Axel Schubert, Livia Visai, Mauro Torti, J. Ross Fitzgerald, Timothy J. Foster,
Dieter J. Reinscheid, and Pietro Speziale
The bacterium Streptococcus agalactiae
is an etiologic agent in the pathogenesis
of endocarditis in humans. FbsA, a fibrino-
gen-binding protein produced by this
pathogen, is considered an important viru-
lence factor. In the present study we
provide evidence that S agalactiae clini-
cal isolates bearing FbsA attach to fibrino-
gen and elicit a fibrinogen-dependent
aggregation of platelets. Mutants of
S agalactiae lacking the fbsA gene lost
the ability to attach to fibrinogen and to
aggregate platelets. Plasmid-mediated ex-
pression of fbsA restored the capability
for fibrinogen binding and platelet aggre-
gation in S agalactiae fbsA mutants, and
allowed Lactococcus lactis to interact
with fibrinogen and to aggregate human
platelets. Moreover, a monoclonal anti-
FbsA antibody inhibited bacterial adher-
ence to fibrinogen and S agalactiae–
induced platelet aggregation. Platelet
aggregation was inhibited by aspirin,
prostaglandin E1, the peptide RGDS, and
the antibody abciximab, demonstrating
the specificity of platelet aggregation by
S agalactiae and indicating an involve-
ment of integrin glycoprotein IIb/IIIa in the
induction of platelet aggregation. Aggre-
gation was also dependent on anti-FbsA
IgG and could be inhibited by an antibody
against the platelet FcRIIA receptor.
These findings indicate that FbsA is a
crucial factor in S agalactiae–induced
platelet aggregation and may therefore
play an important role in S agalactiae–
induced endocarditis. (Blood. 2005;105:
1052-1059)
© 2005 by The American Society of Hematology
Introduction
Streptococcus agalactiae (group B streptococcus [GBS]) is an
important human pathogen that causes pneumonia, sepsis, and
meningitis in neonates. It also poses a significant threat to
immunocompromised adults in whom it is responsible for celluli-
tis, arthritis, urinary tract infections, and endocarditis.1,2 Adherence
to extracellular matrix components and invasion of pulmonary
epithelium may be a prerequisite for infection. In fact, like other
pathogens, S agalactiae appears to attach to host extracellular
matrix proteins such as fibronectin3,4 and laminin.5
Several studies have also demonstrated the binding of
S agalactiae to fibrinogen (Fbg)6,7 and recently, the isolation of the
fbsA gene has been reported, which encodes an Fbg receptor from
S agalactiae.8 The fbsA gene encodes a protein that possesses
structural similarity to many cell surface-associated proteins from
gram-positive bacteria including a typical cell wall attachment
region comprising an LPKTG motif, an hydrophobic transmem-
brane sequence, and an intracytoplasmic C-terminus. In addition,
the protein contains a signal sequence for secretion and a domain
composed of repetitive units, each 16 amino acids in length, located
just outside the cell wall attachment region. Different S agalactiae
strains possess various numbers of repetitive units in the FbsA
protein, being the basis of size heterogeneity of FbsA.
The repeat region of FbsA was demonstrated to bind to Fbg and
to inhibit the attachment of the bacteria to human Fbg. Even a
single repeat unit was shown to bind to Fbg and to interfere with the
binding of S agalactiae to Fbg. The repeat units of the FbsA are
highly similar to each other and contain a consensus sequence for
Fbg binding. The consensus motif could not be identified in
Fbg-binding proteins from other organisms, indicating that it
represents a novel type of Fbg-binding site.8 Numerous Fbg-
binding proteins have so far been identified from different bacterial
species, in particular staphylococci9-13 and streptococci.14-16 The
ability of surface proteins from Staphylococcus aureus to bind Fbg
is believed to be important in promoting the bacterial adherence to
host tissues during an infection and may serve as a mechanism for
colonization of the cardiac tissue in infective endocarditis.17,18 In
line with this, Fbg-immobilized S aureus or Streptococcus pyo-
genes cells induce aggregation of flowing platelets and thrombus
formation.19
Cases of S agalactiae–induced endocarditis in adults have been
reported more frequently in recent years and are usually associated
with predisposing conditions such as alcoholism and diabetes
mellitus although endocarditis caused by S agalactiae in healthy
adults has also been described.20-23 S agalactiae strains, possessing
Fbg-binding activity, were previously shown to induce platelet
aggregation and to be involved in disseminated intravascular
coagulation in mice.24 Because crude extracts of S agalactiae
strains, exhibiting significant Fbg-binding activity, were able to
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inhibit platelet aggregation, it was suggested that the Fbg-binding
activity of S agalactiae participates in platelet aggregation.24
Subsequent studies revealed that S agalactiae uses a proteinaceous
factor for platelet aggregation;25 however, the molecular basis for
this interaction remained unknown. These findings raise the
question whether the S agalactiae Fbg receptor, FbsA, is involved
in bacterial platelet aggregation and thereby plays a role in
S agalactiae-triggered cardiovascular diseases such as endocarditis.
In the present report, we show that S agalactiae strains bearing
FbsA attach to Fbg and induce a Fbg-dependent platelet aggrega-
tion. In addition, we provide evidence that specific antibodies
bound to surface-immobilized FbsA promote platelet aggregation
through an independent interaction with the FcRIIA receptor.
Materials and methods
Proteins
Human Fbg (Calbiochem, San Diego, CA) was made free of contaminating
fibronectin by purification over a gelatin-Sepharose column. IgG contami-
nants from fibronectin-free Fbg were removed by affinity chromatography
through a protein G-Sepharose column. The monoclonal antibody (mAb)
IV.3 was isolated from the supernatant of an hybridoma clone obtained from
the American Type Culture Collection (Manassas, VA). ReoPro was
generously provided by Dr A. Barattini (Eli Lilly, Indianapolis, IN). ReoPro
contains abciximab, a Fab fragment of the mAb 7E3 against glycoprotein
(GP) IIa/IIIb. IgG from human sera were purified on a protein G-Sepharose
column. FbsA-specific antibodies from human IgG were removed by
absorption on Sepharose coupled with FbsA. Other laboratory reagents
were from Sigma (St Louis, MO).
Bacterial strains and culture conditions
The S agalactiae strains 706 S2 (serotype Ia), 176 H4A (serotype II), 6313
(serotype III), and SS 1169 (serotype V) have been described previously.26
Strain 7805 (serotype Ib) was kindly provided by G. S. Chhatwal
(Department of Microbial Pathogenesis and Vaccine Research, German
Research Center for Biotechnology [GBF], Braunschweig, Germany), and
strain 1504 (serotype V) was obtained from the collection of the National
Reference Center for Streptococci in Aachen, Germany. S agalactiae was
cultivated at 37°C in Todd-Hewitt broth containing 1% yeast extract. The
recombinant S agalactiae clone, carrying the plasmid pOri23 was selected
with erythromycin (5 g/mL). Lactococcus lactis strain MG136327 was
used for heterologous gene expression. L lactis was grown at 30°C in M17
medium (Oxoid, Basingstoke, United Kingdom), supplemented with 0.5%
glucose, and the strain carrying the pOri23 derivative was selected with
erythromycin (5 g/mL). Escherichia coli DH528 was used for cloning
purposes and E coli BL2129 served as host for the production of FbsA fusion
proteins. E coli was grown at 37°C in Luria broth (LB) and clones carrying
plasmid pET28a were selected in the presence of kanamycin (50 g/mL).
Construction of fbsA deletion mutants
The fbsA gene was deleted in the chromosome of various S agalactiae
strains as previously described by Schubert et al.8
Plasmid-mediated expression of fbsA
The promotorless fbsA gene, including its ribosomal binding site, was
cloned into the expression vector pOri23.30 The construction of plasmid
pOrifbsA has been described previously.31 The pOri23-derived plasmid was
transformed by electroporation into S agalactiae and L lactis with
subsequent erythromycin selection. L lactis cells were made competent and
transformed as described elsewhere.32 Surface expression of FbsA by
transformants of S agalactiae strains and L lactis or loss of fbsA gene in S
agalactiae mutants was verified by immunofluorescence microscopy.
Hexahistidyl-tagged FbsA fusion protein, carrying 19 internal repeats, was
produced and purified as described previously.8
Synthesis of the repeated unit of FbsA
A synthetic peptide corresponding to the repeat unit of FbsA (GNVLERRQR-
DAENRSQ) was synthesized by Primm (San Raffaele Biomedical Science
Park, Milan, Italy). The peptide was analyzed for homogeneity by
high-performance liquid chromatography (HPLC) using a C18 column and
mass spectrometry. During the peptide synthesis a cysteine was added to the
C-terminal end of the amino acid sequence that served for the coupling of
ovalbumin (OVA) or keyhole limpet hemocyanin (KLH). The peptide was
coupled to the carrier protein using sulfosuccinimidyl 4-(N-maleimidom-
ethyl)-cyclohexane-1-carboxylate (sulfoSMCC; Pierce Chemical, Rock-
ford, IL) following the instructions of the manufacturer.
Generation of mAbs
The mAbs against the synthetic FbsA repeated unit were produced
essentially as described by Ko¨hler and Milstein33 with minor modifica-
tions.34 BALB/c mice were immunized by injection with the repeat unit
conjugated with KLH. Hybridoma supernatants were screened for reactivity
with the synthetic peptide-OVA conjugate immobilized on microtiter plates
and positive clones were further characterized by enzyme-linked immunosor-
bent assay (ELISA) and Western blot.
Antibody purification and isotyping
The antibodies were purified from supernatants of hybridomas by using
ammonium sulfate precipitation, followed by affinity chromatography on
protein G-Sepharose column according to the recommendations of the
manufacturer (Amersham Pharmacia Biotech, Piscataway, NJ). Isotyping
of the produced mAbs was performed using a Mouse-Typer subisotyping
kit (Bio-Rad, Hercules, CA). The mAb 5H2 was found to belong to subtype
IgG1-k and the mAb 2B1 to subtype IgG2b-k.
ELISAs
Assays were performed as detailed elsewhere.34
Electrophoresis and blotting
Plasma proteins absorbed by and eluted from S agalactiae cells were
fractionated on 7.5% polyacrylamide gels and then electroblotted onto
a nitrocellulose membrane (Amersham Pharmacia Biotech) as previ-
ously reported.35
Attachment of S agalactiae strains to Fbg
Microtiter plates were coated overnight at 4°C with 1 g human purified
Fbg in 100 L 50-mM Na2CO3, pH 9.5. The wells were washed 3 times
with phosphate-buffered saline (PBS) and then blocked with 1% bovine
serum albumin for 2 hours. Then, 5  107 cells of S agalactiae were added
to each well and the plates were incubated for 2 hours at 22°C. After
extensive washing of the plates, 1 g rabbit anti-S agalactiae IgG was
added to each well, followed by a further incubation for 90 minutes.
Subsequently, peroxidase-conjugated goat anti–rabbit IgG was added, and a
color reaction developed after the addition of o-phenylenediamine. Absor-
bance at 490 nm was quantitated in a microplate reader (Bio-Rad).
Platelet preparation
Blood was collected from informed healthy volunteers who had not taken
any nonsteroidal anti-inflammatory drugs during the previous 10 days. Nine
volumes of blood were added to 1 volume of 3.8% sodium citrate (130 mM
citric acid, 152 mM Na citrate, and 112 mM glucose). Platelet-rich plasma
(PRP) was obtained by centrifugation of anticoagulated whole blood at
120g for 10 minutes at 22°C. Approval was obtained from the University
of Pavia. Informed consent was provided according to the Declaration
of Helsinki.
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For platelet isolation, PRP was centrifuged at 300g for 10 minutes and
resuspended in 0.4 mL 10 mM HEPES (N-2-hydroxyethylpiperazine-N-2-
ethanesulfonic acid) containing 137 mM NaCl, 2.9 mM KCl, 12 mM
NaHCO3, pH 7.4 (HEPES buffer). Platelets were isolated on a 10-mL
column of Sepharose Cl-2B that was pre-equilibrated with HEPES buffer.
Platelet number was adjusted to 1  109 cells/mL with the same buffer.
Platelet aggregation
PRP (0.4 mL) was incubated at 37°C in an aggregometer (Chrono-Log,
Havertown, PA) under constant stirring and stimulated with 10 M
adenosine diphosphate (ADP) or 50 l of a S agalactiae 6313 suspension
(1  109 cells/mL). To examine the effect of various inhibitors of platelet
aggregation, PRP was pretreated for 5 minutes with 1 mM Arg-Gly-Asp-Ser
(RGDS), the antibody abciximab (10 g/mL), 1 M prostaglandin E1
(PGE1), or apyrase (10 U/mL), or for 20 minutes with 1 M aspirin (ASA)
prior to the addition of ADP or S agalactiae 6313 cells.
In experiments with gel-filtered platelets (GFPs), 1  109 cells of
S agalactiae 6313 were preincubated for 30 minutes in an end-over-end
mixer with 1 mL human plasma or physiologic plasma concentrations of
purified Fbg (3 mg/mL), fibronectin (300 g/mL), or albumin (35 mg/mL).
After washing, bacteria were suspended in 1 mL HEPES buffer containing
1.25 mM CaCl2 and 5.5 mM glucose, pH 7.4. Then, 50 L of each
streptococcal suspension was added to 0.4 mL (4  108) GFPs in HEPES
buffer containing 1.25 mM CaCl2 and 5.5 mM glucose, pH 7.4, and
aggregation was monitored in the reaction mixture. The rate and extent of
platelet aggregation was detected as the percentage of light transmission
and presented as aggregation tracings.
Measurement of cytosolic Ca2 concentration
Cytosolic Ca2 concentration in Fura-2/AM–loaded GFPs was determined
as previously described.36 Measurement of Ca2 was performed on 0.4-mL
platelet suspensions (2  108/mL) prewarmed at 37°C under gentle stirring
in a Perkin-Elmer (Norwalk, CT) LS3 spectrofluorometer in the presence of
1 mM CaCl2. Fura-2 fluorescence signals were calibrated according to the
method of Pollock et al.37
Results
S agalactiae cells expressing FbsA selectively absorb Fbg from
human plasma
To determine the importance of FbsA in the interaction of
S agalactiae with Fbg, the FbsA-expressing S agalactiae strain
6313 and its isogenic mutant 6313 fbsA were tested for their
ability to sequester Fbg from human plasma. Bacteria-bound
plasma proteins were eluted at low pH, separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
under either reducing or nonreducing conditions and subsequently
stained with Coomassie (Figure 1A). Separation of bacteria-bound
plasma proteins revealed for S agalactiae 6313 under reducing
conditions 3 major protein bands of 67, 55, and 48 kDa that were
not present in the eluate of mutant 6313 fbsA. Determination of
internal sequences of the proteins absorbed by 6313 showed 100%
identity to regions in the A, B, and  chains of human Fbg.
The identity of the Fbg chains bound to S agalactiae 6313 was
further confirmed by Western blot analysis with an anti-Fbg
antibody (Figure 1B). In the lane where the proteins absorbed by
strain 6313 had been separated under nonreducing conditions, the
antibody reacted with a 340-kDa band, a band of similar size of
purified Fbg. Conversely, no signal was detected by Western blot in
the lane where proteins bound to the isogenic fbsA deletion mutant
had been separated. Similar results were obtained when bacteria-
bound proteins were eluted and tested by ELISA (data not shown).
Together, these data suggest that Fbg binding by S agalactiae can
occur in vivo and that it is mediated by FbsA. Moreover, because
the Fbg-corresponding bands were the most prominent after
Coomassie staining, our findings indicate that Fbg represents the
main plasma ligand for GBS.
FbsA mediates binding of S agalactiae to Fbg
In strain 6313 the FbsA protein represents the major Fbg-receptor
of these bacteria.8 To test the importance of FbsA for the
Fbg-binding of different S agalactiae strains, the fbsA gene was
deleted in the genome of 6 clinical S agalactiae isolates, belonging
to the medically relevant serologic groups Ia, Ib, II, III, and V,
respectively. The parental strains and their isogenic fbsA deletion
mutants were subsequently tested for their attachment to immobi-
lized Fbg. As shown in Figure 1C, the various S agalactiae strains
differed significantly in their interaction with human Fbg. How-
ever, in all of the analyzed strains, the deletion of the fbsA gene
reduced the Fbg binding to background levels. For complementa-
tion studies, we used the L lactis/Streptococcus expression vector
pOri23,30 which replicates in high copy number in gram-positive
bacteria and possesses the strong promoter P23 from L lactis.38
Figure 1. FbsA mediates absorption of Fbg from human plasma and attachment
of S agalactiae to Fbg. In panels A and B the FbsA-dependent absorption of plasma
Fbg by S agalactiae strains is reported. The FbsA S agalactiae strain 6313 and its
fbsA	 mutant were mixed with human plasma. Subsequently, bacteria-bound
proteins were eluted and subjected to electrophoresis on an 7.5% polyacrylamide gel
under reducing () and nonreducing conditions (	) and then Coomassie stained (A)
or probed by Western blot (B). The Coomassie-stained gel and Western blot show a
reference sample of pure human Fbg and proteins absorbed and eluted from
bacteria, as indicated. Immunostaining was performed by incubating the membrane
with mouse IgG raised against human Fbg. No Fbg bands were detected on a blot
containing plasma proteins bound to the fbsA	 mutant. Molecular mass markers (left)
are in kilodaltons. In panel C, the adherence of S agalactiae strains to Fbg is reported.
Microtiter plates were coated with fibrinogen (10 g/mL) and incubated for 2 hours
with 5  107 cells belonging to different serotypes. After extensive washes, 1 g
rabbit anti–GBS IgG was added to each well, followed by an incubation for 90
minutes. Attachment of the bacteria was quantified by addition of peroxidase-conjugated
goat anti–rabbit IgG and the plates were developed with o-phenylenediamine. The bars
show SDs of triplicate samples.
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Vector pOri23 was transformed into S agalactiae 6313, and the
plasmids pOri23 and pOrifbsA were introduced into mutants 6313
fbsA. The resultant strains were subsequently tested for their
Fbg-binding capability. The presence of the pure vector pOri23 did
not influence the binding of the S agalactiae strains 6313 and 6313
fbsA to immobilized Fbg, whereas plasmid-mediated expression
of fbsA increased the Fbg-binding of strain 6313 fbsA pOrifbsA to
about 80% of wild-type level. These findings show that plasmid-
mediated expression of fbsA can restore the Fbg binding of
S agalactiae 6313 fbsA. Our results also demonstrate that the
impaired Fbg binding of the fbsA mutant is caused by its fbsA
deficiency and not by unrelated mutations in its chromosome. To
test if FbsA alone is sufficient for Fbg binding, we transformed the
plasmids pOri23 and pOrifbsA into L lactis, a gram-positive
organism that naturally does not interact with human Fbg. Whereas
strain L lactis pOri23 did not interact with Fbg, strain L lactis
pOrifbsA revealed significant binding to Fbg, being in the same
magnitude as that of S agalactiae 6313 fbsA pOrifbsA. These
results demonstrate that the fbsA gene is sufficient to confer
Fbg-binding activity to different gram-positive bacteria.
An mAb against the repeat unit of FbsA blocks adherence
of S agalactiae to Fbg
A panel of mouse mAbs was generated against a synthetic analog
of the repetitive unit of FbsA conjugated with KLH. Two of the
generated mAbs, 5H2 and 2B1, were further characterized. As
expected, both the mAbs recognized the synthetic peptide or the
peptide conjugated to KLH or OVA, whereas no reactivity was
detected with KLH or OVA alone or with an unrelated peptide of
similar size (data not shown). As shown in Figure 2A, mAbs 5H2
and 2B1 bound to FbsA-coated wells in a concentration-dependent
manner and exhibited similar saturation isotherms. The mAbs were
examined for their ability to interfere with the binding of biotin-
labeled Fbg to immobilized FbsA. The mAb 5H2 substantially
inhibited the interaction of FbsA with human Fbg when added to
the microtiter wells at a concentration of 2 g/well (Figure 2B). In
contrast, less than 20% inhibition was obtained with up to
7.5 g/well mAb 2B1. Likewise, in dose-response experiments,
2 g/well mAb 5H2 inhibited the attachment of S agalactiae 6313
to immobilized Fbg by more than 95%, whereas up to 7.5 g/well
of control mAb 2B1 reduced the bacterial adherence by only 15%
(Figure 2C). Taken together, these data demonstrate the crucial role
of the internal repeat units of FbsA in mediating the attachment of S
agalactiae to human Fbg.
FbsA plays a critical role in S agalactiae–induced
platelet aggregation
To investigate the role of FbsA in platelet aggregation by S agalac-
tiae, various S agalactiae strains and their isogenic fbsA-deletion
mutants were tested for their ability to induce platelet aggregation.
Typical examples of traces during platelet aggregation are shown in
Figure 3A. The streptococcal strains 706 S2, 6313, and 1504
strongly supported platelet aggregation (lag time, 90 seconds). In
contrast, strains 7805, SS1169, and 176 H4A revealed significantly
longer lag times (4, 10, and 15 minutes, respectively). In general,
the ability of these strains to induce platelet aggregation correlates
with their capability to interact with human Fbg. However, it is
unclear why strains SS1169 and 176 H4A, which exhibit compa-
rable Fbg-binding activity, presented different lag times. The
deletion of the fbsA gene completely abolished the ability of all the
strains to aggregate platelets, suggesting that FbsA is required by S
agalactiae to induce platelet aggregation. Moreover, plasmid-
mediated expression of fbsA in mutant 6313 fbsA restored its
capability to mediate platelet aggregation to about the wild-type
level (Figure 3B).
To further investigate the role of FbsA in the aggregation
process, L lactis pOri23 and L lactis pOrifbsA were tested for their
ability to induce platelet aggregation. As shown in Figure 3C,
L lactis pOri23, carrying the empty vector, did not cause any
aggregation of platelets, whereas L lactis pOrifbsA aggregated
platelets at levels that were similar to those of S agalactiae
6313. The results presented unambiguously demonstrate that
FbsA expression is a prerequisite for platelet aggregation by
S agalactiae cells.
S agalactiae–induced platelet aggregation is a
genuine aggregation
To demonstrate that the observed aggregation is the effect of a true
platelet activation and is thus a genuine aggregation, S agalactiae-
induced aggregation was performed in the presence of specific
platelet activation inhibitors (Figure 4). PGE1 is a substance that
elevates the intracellular cyclic adenosine monophosphate (cAMP)
Figure 2. Effect of mAbs, directed against the repeat region of FbsA, on the
interaction of S agalactiae 6313 or FbsA with human Fbg. (A) Concentration-
dependent binding of the anti-FbsA mAbs 5H2 (f) and 2B1 () to FbsA. Microtiter
wells were coated overnight with 500 ng FbsA in 50 mM sodium carbonate, pH 9.5.
The wells were treated for 1 hour at 22°C with 200 L PBS containing 2% bovine
serum albumin (BSA) and washed 5 times with PBS with 0.1% vol/vol Tween 20
(PBST). The plates were incubated with increasing amounts of mAbs 5H2 or 2B1 and
the binding of each antibody was detected by incubating the wells with a 1:1000
dilution of rabbit antimouse peroxidase-conjugated polyclonal antibody. After wash-
ing, binding was quantitated using the substrate o-phenylenediamine dihydrochloride
and measuring the absorbance at 490 nm. (B) The effect of mAbs 5H2 or 2B1 on the
binding of fibrinogen to immobilized FbsA is reported. FbsA was immobilized onto
microtiter wells (500 ng/well) and incubated with biotin-labeled human Fbg in the
presence of the indicated concentrations of mAbs 5H2 or 2B1. After washing, binding
of the ligand was quantitated by the addition of avidin-conjugated peroxidase and
development with o-phenylenediamine. (C) To analyze the effect of the anti-FbsA
mAbs on S agalactiae 6313 attachment to Fbg, microtiter wells were coated with Fbg
(1 g/well). Bacteria (5  107/well) were preincubated with the indicated amounts of
mAbs 5H2 or 2B1 and transferred to the Fbg-coated wells and the suspension was
incubated for 2 hours. After extensive washes, 1 g rabbit anti-GBS IgG was added to
the wells, followed by an incubation for 90 minutes. Adherent cells were detected by
peroxidase-conjugated goat anti–rabbit IgG and the plates were developed with
o-phenylenediamine. All the data are expressed as percentage of bound Fbg or
attached bacteria in the absence of mAbs. The bars show SDs of triplicate samples.
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and thereby inhibits platelet aggregation. Preincubation of platelets
with PGE1 completely inhibited S agalactiae–induced platelet
aggregation, verifying that S agalactiae activates platelets prior to
aggregation and that this process is thus a genuine aggregation.
Aggregation was also inhibited by ASA, a cyclooxygenase inhibi-
tor, suggesting a role of thromboxane A2 in the aggregation process.
However, apyrase (ADPase), an adenosine diphosphatase, failed to
inhibit S agalactiae–induced aggregation, indicating that aggrega-
tion is not dependent on ADP secretion during activation. In
contrast, apyrase completely inhibited ADP-induced platelet aggre-
gation. Interestingly, peptide RGDS and the GPIIb/IIIa antibody
inhibitor abciximab prevented bacteria-triggered aggregation sug-
gesting that GPIIb/IIIa is involved in S agalactiae–induced platelet
aggregation. Activation is the prerequisite of platelet aggregation.
Among the earliest detectable biochemical responses of platelet
activation is cytosolic calcium increase. To clarify whether S aga-
lactiae cells drive an increase of intracellular calcium levels, GFPs
were loaded with Fura-2 and then incubated with bacteria in the
presence or absence of Fbg (Figure 4B). S agalactiae preincubated
with Fbg induced a significant increase in cytosolic Ca2, whereas
no signal was observed with platelets incubated with bacteria or
Fbg alone.
mAb 5H2 interferes with platelet aggregation induced
by S agalactiae
The mAb 5H2, which blocks the binding of S agalactiae to Fbg,
was tested for its impact on S agalactiae–induced platelet aggrega-
tion. As depicted in Figure 5, S agalactiae–induced platelet
aggregation was significantly blocked by mAb 5H2. In contrast,
isotype-matched mAb 2B8, an mAb raised against the S aureus
protein CNA, did not interfere with bacteria-induced platelet
aggregation, suggesting that the inhibition of mAb 5H2 was
specific. Moreover, mAb 2B1, which recognizes the internal
repeats of FbsA without blocking the attachment of S agalactiae to
Fbg, did not affect S agalactiae–induced platelet aggregation (data
not shown).
Fbg is required for S agalactiae–induced platelet aggregation
To investigate the role of human Fbg in S agalactiae–induced
platelet aggregation, aggregation experiments were performed with
platelets in human plasma and in plasma-free medium. As depicted
in Figure 6A, S agalactiae aggregated GFPs suspended in plasma,
but not in plasma-free medium, suggesting the involvement of a
plasma factor in the aggregation process. Because GFPs do not
aggregate in the presence of serum (Figure 6A) and Fbg is present
in plasma and is the natural ligand for the platelet receptor
GPIIb/IIIa, we investigated the role of Fbg in S agalactiae–induced
platelet aggregation (Figure 6B). As a matter of fact, the addition of
Fbg triggered a prompt and specific aggregation of GFP by
S agalactiae, whereas other plasma proteins such as fibronectin or
albumin had no effect on platelet aggregation. Taken together, our
Figure 5. Inhibitory effect of mAb 5H2 on platelet aggregation induced by S
agalactiae 6313. Fifty microliters of S agalactiae cells (5  107) were preincubated
with 5 g mAb 5H2 or an equal concentration of isotype-matched control mAb 2B8
and then tested for their ability to activate platelet aggregation in PRP (0.4 mL) as
reported in “Materials and methods.” The data are representative of 3 experiments.
Figure 3. FbsA-dependent platelet aggregation by S agalactiae and L lactis
strains. The ability of S agalactiae strains belonging to different serotypes and their
corresponding mutants (fbsA) to activate platelet aggregation in PRP was tested (A). The
results are presented as percentage aggregation. In the panels the serotype of each
strain is indicated. The aggregation tracings are representative of the data from 4
independent experiments performed in triplicate. Panel B shows platelet aggregation
induced by the S agalactiae strains 6313 pOri23, 6313fbsA pOri23, and 6313fbsA
pOrifbsA. Panel C shows platelet aggregation elicited by L lactis pOri23 and L lactis
pOri23fbsA. The results are presented as percentage aggregation. The data were
derived from 3 independent experiments performed in triplicate.
Figure 4. Mechanism of S agalactiae–induced platelet activation/aggregation.
(A) Effect of inhibitors on S agalactiae 6313-induced platelet aggregation. PRP
(0.4 mL) was pretreated with 1 mM RGDS, abciximab (10 g/mL), 1 M PGE1, or
apyrase (10 U/mL) for 5 minutes or with 1 M ASA for 20 minutes prior to the
induction of platelet aggregation by 10 M ADP (f) or S agalactiae 6313 cells
(5  107; ). Results are expressed as percentage of aggregation performed in the
absence of antagonists. Each data point is the mean 
 SD of 4 experiments. (B) S
agalactiae cells induce cytosolic Ca2 increase in platelets. Fura-2/AM-loaded
platelets (8  107 in 0.4 mL) were stimulated with 2.5  105 or 2.5  106 cells of S
agalactiae 6313 in the presence of Fbg (3 mg/mL). Trace of Ca2 increase by
thrombin (1 U/mL) is shown as control. The effect of either bacteria or Fbg on Ca2
increase in platelets is also reported. The arrows indicate the addition of agonist to
platelets. Results are representative of 3 experiments.
1056 PIETROCOLA et al BLOOD, 1 FEBRUARY 2005  VOLUME 105, NUMBER 3
 For personal use only. by guest on January 3, 2014. bloodjournal.hematologylibrary.orgFrom 
results highlight the importance of FbsA and Fbg in S agalactiae-
triggered platelet aggregation.
Fbg is not the sole plasma factor that mediates platelet
aggregation by S agalactiae
Besides Fbg, antibodies against different pathogenic bacteria
induce platelet aggregation by binding to the FcRIIA IgG receptor
on platelets.19,39 To investigate the possibility of anti-S agalactiae
antibodies as additional mediators of platelet aggregation, an
unfractionated human Fbg preparation that contained trace
amounts of IgG was passed through an affinity column of
protein G–Sepharose. Fbg present in the flow-through was col-
lected separately. The column was washed extensively and bound
antibodies were subsequently eluted with 0.1 M glycine, pH 2.8,
and neutralized. IgG isolated from the affinity matrix represented
0.5% of the unfractionated protein. When examined for the
anti-FbsA antibody level in an ELISA format, the unfractionated
Fbg and affinity-purified IgG reacted with FbsA, whereas the
IgG-depleted Fbg did not (Figure 7A inset). In a S agalactiae–
induced aggregation assay, GFP aggregation mediated by IgG-free
Fbg was about 35% reduced in comparison with the aggregation
stimulated by unfractionated Fbg (the control). Moreover, a
significant aggregation (24% of the control) was observed incubat-
ing GFPs with S agalactiae cells in the presence of affinity-purified
IgG. Together, these data indicate that anti-FbsA IgG may also
support GFP aggregation. In line with this, antibody IV.3, which is
directed to the FcRIIA receptor on human platelets, substantially
inhibited GFP aggregation by S agalactiae in the presence of
unfractionated Fbg but not in the presence of IgG-depleted Fbg
(Figure 7A).
FbsA IgG supports platelet aggregation by S agalactiae
The results reported in Figure 7A prompted us to screen IgG
isolated from sera of different individuals for reactivity to FbsA.
This analysis resulted in a considerable variability in the anti-FbsA
antibody titer (Figure 7B). Interestingly, the IgG fraction from
donor no. 19 revealed a high antibody titer against FbsA and
strongly stimulated S agalactiae–induced GFP aggregation. In
contrast, IgG from volunteer no. 20 revealed no reactivity with
FbsA and neither supported GFP aggregation by S agalactiae
(Figure 7C). Similar results were obtained with a number of other
positively and negatively FbsA reactive IgG donors. Of note, the
aggregation percent was related to the anti-FbsA antibody titer
(data not shown). In the absence of Fbg, mouse IgG did not affect
GFP aggregation elicited by S agalactiae and, unlike human
immunoglobulins, poorly supported platelet adherence (data not
shown), suggesting a low affinity of mouse IgG for human
FcRIIA. Preincubation of GFPs with mAb IV.3 neutralized the
IgG-mediated effect on platelet aggregation elicited by S agalac-
tiae (Figure 7C).
Figure 7. Role of specific anti-FbsA antibodies in S agalactiae–induced platelet
aggregation. (A) S agalactiae cells (1  109) were mixed for 1 hour with 3 mg/mL
unfractionated Fbg, Fbg from which IgG had been removed, or with 625 g/mL
affinity-purified antibodies. Bacteria were harvested by centrifugation, washed, and
adjusted to 1  109 cells/mL. Then, 50 L of the bacterial suspension was added to
0.4 mL GFPs (4  108) and tested for platelet aggregation as reported in Figure 6. To
examine the effect of FcRIIA on platelet aggregation, 0.4 mL GFPs was preincu-
bated for 10 minutes with the anti-FcRIIA antibody IV.3 (20g/mL), mixed with 50L
of a S agalactiae suspension previously treated with unfractionated Fbg or IgG-free
Fbg and then tested for aggregation. (A inset) ELISAs were performed to quantify the
level of anti-FbsA antibodies in unfractionated Fbg, IgG-depleted Fbg, or affinity-
purified IgG. The assay was performed by incubating FbsA-coated microtiter wells (2
g/well) with 7.5 g protein of each fraction followed by the addition of peroxidase-
conjugated rabbit antihuman IgG. (B) The reactivity of IgG from human donors to
recombinant FbsA. Microtiter wells were coated with recombinant FbsA
(1 g/100 L) and incubated with each IgG preparation (2 /100 L) for 2 hours at
22°C. Bound antibody was detected with peroxidase-conjugated rabbit antihuman
IgG. (C) Cells of S agalactiae (1  109) were preincubated for 1 hour with 100 g/mL
IgG from an individual with a high anti-FbsA antibody titer (donor no. 19), washed,
and adjusted to 1  109 cells/mL. Then, 50 L of the bacterial suspension was added
to 0.4 mL GFPs (4  108), previously incubated with or without the anti-FcRIIA
antibody IV.3 according to the conditions described in panel A, and tested for platelet
aggregation as reported. The effects of IgG from donor no. 19 depleted of anti-FbsA
antibodies and of donor no. 20, who lacks anti-FbsA antibodies on GFP aggregation
by S agalactiae, are also reported. All the results are representative of those
observed in 3 separate experiments.
Figure 6. Effect of whole plasma and purified plasma proteins on S agalactiae–
induced aggregation of GFPs. Cells of S agalactiae 6313 (1  109) were preincu-
bated for 1 hour with 1 mL whole human plasma, human serum, or 0.9% solution of
NaCl (A) or physiologic concentrations of Fbg (3 mg/mL), fibronectin (300 g/mL), or
albumin (35 mg/mL; panel B). Bacteria were harvested by centrifugation, washed,
and adjusted to 1  109 cells/mL. Then 50L of the bacterial suspensions was added
to 0.4 mL GFPs (4  108) in HEPES buffer supplemented with 1.25 mM CaCl2 and
5.5 mM glucose, pH 7.4, and the samples were monitored in an aggregometer for
turbidity. Results are representative of 3 different experiments.
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To examine the specificity of IgG-mediated platelet aggregation
in more detail, IgG from donor no. 19 was passed through an
FbsA-Sepharose affinity column. The flow-through, which was
depleted of anti-FbsA IgG, did not stimulate platelet-aggregation in
the presence of S agalactiae (Figure 7C), suggesting a role of
anti-FbsA antibodies in S agalactiae–induced platelet aggregation.
Taken together, our findings suggest an involvement of human
anti-FbsA IgG and the platelet receptor FcRIIA in S agalactiae–
induced platelet aggregation.
Discussion
In the general interaction between pathogenic bacteria and the host,
the ability of microbes to activate and aggregate platelets represents
an emerging topic. Platelet binding and aggregation in infective
endocarditis pathogenesis was initially described in Streptococcus
sanguis40 and shown to be the effect of a direct interaction between
platelet GPIb protein and S sanguis.41 It also has been reported that
Helicobacter pylori, the causative agent of peptic ulcers and gastric
carcinoma, induces platelet aggregation via GPIb and that anti-H
pylori antibodies play a direct role in platelet response.39 S aureus
produces 4 surface proteins that can recognize Fbg, namely, ClfA,
ClfB, FnbpA, and FnbpB.9-13 Expressing individual determinants
such as ClfA in the nonpathogenic bacterium L lactis, O’Brien et
al42 demonstrated multiple mechanisms for the activation of
platelets by S aureus and identified redundant, Fbg-dependent roles
of ClfA and ClfB in platelet aggregation. A mechanism of platelet
aggregation similar to that observed in S aureus has been described
in S pyogenes strains expressing the Fbg-binding proteins M1, M3,
and M5.19 Furthermore, if antibodies against bacteria are present in
the blood, IgG may bind to surface-expressed bacterial antigens
and aggregate platelets through an interaction with FcRIIA.19
In this work, we demonstrate that S agalactiae strains, belonging to
different serotypes, promoted platelet aggregation, suggesting that the
aggregation process is independent of the S agalactiae serotype.
S agalactiae–induced platelet aggregation was inhibited by ASA and
PGE1 and by antagonists of integrin GPIIb/IIIa, such as the peptide
RGDS and the antibody abciximab, indicating that S agalactiae triggers
a true aggregation that is both thromboxane- and GPIIb/IIIa-dependent.
This information was further supported by the finding that platelet
aggregation induced by S agalactiae involved intracellular calcium
movements. The S agalactiae–induced aggregation assay carried out
with GFPs did not result in aggregation unless exogenous Fbg was
supplemented. This finding indicates that Fbg is an essential component
of S agalactiae-mediated platelet aggregation. In thrombin-induced
aggregation, Fbg is released into the exterior by  granules of the
platelets. In contrast, S agalactiae–induced aggregation was shown to
require exogenous Fbg, indicating that the bacteria are weaker agonists
for platelet aggregation than thrombin.
We also found that S agalactiae aggregation activity requires FbsA,
a recently identified S agalactiae surface Fbg-binding protein. Several
lines of evidences support this hypothesis. First, fbsA deletion mutant
strains neither bind to Fbg nor induce platelet aggregation compared to
the parental strains. Conversely, plasmid-mediated expression of fbsA in
an fbsA deletion mutant restored its ability to interact with human
fibrinogen and to aggregate platelets. Second, mAb 5H2, directed
against the repeat unit of FbsA, dose-dependently inhibited fibrinogen
binding and induction of platelet aggregation by S agalactiae. Third,
expression of FbsA in the surrogate gram-positive bacterium L lactis
conferred to this organism the ability to bind to Fbg and to induce
platelet aggregation. Taken together, these data demonstrate that the
ability of S agalactiae to bind to Fbg and to induce platelet aggregation
are both dependent on FbsA expression.
As with other bacteria,19,39 platelet aggregation by S agalactiae was
also found to be IgG-dependent. In our report we provide evidence that
anti-FbsA IgG is specifically involved in platelet aggregation because
anti-FbsA–depleted human serum did not support aggregation. In line
with this, sera from individuals with a low anti-FbsA IgG titer revealed
little or no platelet aggregation, whereas sera from persons with a high
anti-FbsA IgG titer induced strong platelet aggregation. In addition, our
data suggest a role of the platelet receptor FcRIIA in the aggregation
process because an anti-FcRIIA antibody inhibited IgG-dependent
platelet aggregation by S agalactiae.
Based on our findings, 2 independent mechanisms for S agalactiae–
induced platelet aggregation can be envisaged. First, invading
S agalactiae cells may bind plasma Fbg, to which platelets adhere by
integrin GPIIb/IIIa, resulting in the formation of bacteria/platelet com-
plexes that can develop to large coaggregates. Second, if blood contains
antibodies against FbsA, S agalactiae-bound IgG might cluster FcRIIA
receptors, leading to the activation and aggregation of platelets.
Cases of bacterial endocarditis caused by S agalactiae have been
reported in recent years, usually in association with underlying cardiac
or systemic disorders. S agalactiae endocarditis is generally character-
ized by an acute onset, the presence of large vegetations that have a high
tendency to result in embolism, rapid valve destruction, and a fatal
outcome if appropriate treatment is not started in time. With the present
analysis we proved the notion that S agalactiae cells share with S aureus
and S pyogenes similar mechanisms in eliciting platelet aggregation,
including the attachment of platelets to bacteria-bound Fbg or IgG or
both. However, a variety of other independent platelet activation
mechanisms are effective in S aureus and S pyogenes, whereas our data
suggest that strains of S agalactiae induce platelet aggregation in a
manner that is mainly dependent on FbsA.
A previous study identified the adhesins ClfA and FnbpA from
S aureus as critical inducers of experimental endocarditis in rats.17,18
Thus, it is plausible that FbsA as an etiologic agent of platelet
aggregation contributes to thrombus formation and consequently to the
pathogenesis of S agalactiae-associated endocarditis. Due to the unique
and critical role of FbsA in platelet aggregation, the development of
anti-FbsA strategies could represent an important achievement for the
prevention and treatment of such a life-threatening infective disease.
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